

**Amendments to the Specification:**

Please amend the specification as follows:

*Please replace paragraph number [0029] with the following paragraph. . The amendments to paragraph no. [0029] are indicated by strikethrough and underlining.*

[0029] The "Kabat system" means in the context of the present invention the standard for numbering the residues in a consistent manner according to Kabat (1991; Sequences of Proteins of Immunological Interest, 5.sup.th edit., NIH publication no. 91-3242U.S. Department of Health and Human services) and Chothia (1987; J. Mol. Biol. 196, 901-917). This numbering system is widely used by the skilled artisans and is based on sequence variability and three dimensional loops of the variable domain region which are important in antigen binding activity. All the residues of the light chains or heavy chains have distinct Kabat positions; i.e. the Kabat numbering system applies to CDRs as well as to frameworks. The positions of specific residues of any antibody may be numbered according to Kabat. The numbering system and Kabat positions of specific residues of antibodies are indicated in ~~http://www.bioinf.org.uk/abs~~ www.bioinf.org.uk/abs. For example, the position L24 as mentioned in the invention means the residue 24 in the light chain according to Kabat system. Accordingly, L54 and L96 refer to positions 54 and 96 in the light chain of the antibody according to the Kabat system.

*Please replace paragraph number [0040] with the following paragraph. . The amendments to paragraph no. [0040] are indicated by strikethrough and underlining.*

[0040] It is particularly preferred that the domain which binds to/interacts with the human CD3 complex is characterized by having a serine at position L24, a valine at position L54 and a leucine at position L96. The position L24 means the position 24 in the light chain as described in Kabat (1991; Sequences of Proteins of Immunological Interest, 5.sup.th edit., NIH publication no. 91-3242 U.S. Department of Health and Human services) and Chothia (1987; J. Mol. Biol. 196, 901-917) and in ~~http://www.bioinf.org.uk/abs~~ www.bioinf.org.uk/abs. Similarly, the positions L54 and L96 represent the residues 54 and 96, respectively, of the light chain as described by Kabat and Chothia.

*Please replace paragraph number [0128] with the following paragraph. . The amendments to paragraph no. [0128] are indicated by strikethrough and underlining.*

[0128] These and other embodiments are disclosed and encompassed by the description and Examples of the present invention. Further literature concerning any one of the antibodies, methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries and databases, using for example electronic devices. For example, the public database "Medline", available on the Internet, may be utilized, for example under ~~http://www.ncbi.nlm.nih.gov/PubMed/medline.html~~ www.ncbi.nlm.nih.gov/PubMed/medline.html. Further databases and addresses, such as ~~http://www.ncbi.nlm.nih.gov/~~, www.ncbi.nlm.nih.gov/, ~~http://www.infobiogen.fr/~~, www.infobiogen.fr/, ~~http://www.fmi.ch/biology/researchtools.html~~, www.fmi.ch/biology/researchtools.html, ~~http://www.tigr.org/~~ www.tigr.org/, are known to the person skilled in the art and can also be obtained using, e.g., ~~http://www.lycos.com~~ www.lycos.com or ~~http://www.google.com~~ www.google.com.

*Please replace paragraph number [0136] with the following paragraph. . The amendments to paragraph no. [0136] are indicated by strikethrough and underlining.*

[0136] Elution pattern of bispecific anti-CD19x hum. anti-CD3 antibody containing protein fractions from a Zn-Chelating ~~Fraetogel~~ FRACTOGEL® column.

*Please replace paragraph number [0139] with the following paragraph. . The amendments to paragraph no. [0139] are indicated by strikethrough and underlining.*

[0139] Protein elution pattern from a ~~Sephadex~~ SEPHADEX S200® gel filtration column.